Filing To Observe: Dynavax Technologies Corp: Steve Cohen’s Point72 Asset Management Opened Big New Position

Filing To Observe: Dynavax Technologies Corp: Steve Cohen's Point72 Asset Management Opened Big New Position

The New Steve Cohen’s Point72 Asset Management Holding in Dynavax Technologies Corp

Point72 Asset Management filed with the SEC SC 13G form for Dynavax Technologies Corp. The form can be accessed here: 000089914016001636. As reported in Steve Cohen’s Point72 Asset Management’s form, the filler as of late owns 5.9% or 2,280,608 shares of the Health Care–company.

Dynavax Technologies Corp stake is a new one for the for the hedge fund and it was filed because of activity on September 29, 2016. We feel this shows Steve Cohen’s Point72 Asset Management’s positive view for the stock.

The hedge fund is active investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Steve Cohen’s Point72 Asset Management’s US equities portfolio is in this sector.

Dynavax Technologies Corp Institutional Sentiment

Latest Security and Exchange filings show 144 investors own Dynavax Technologies Corp. The institutional ownership in Q3 2015 is high, at 102.33% of the outstanding shares. This is increased by 12810902 the total institutional shares. 39398183 were the shares owned by these institutional investors. In total 41 funds opened new Dynavax Technologies Corp stakes, 64 increased stakes. There were 14 that closed positions and 30 reduced them.

4 managers had the stock in their top Ten. Notable investors are: New Leaf Venture Partners L.L.C., Amici Capital Llc, Mhr Fund Management Llc..

Cormorant Asset Management Llc is an institutional investor bullish on Dynavax Technologies Corp, owning 575000 shares as of Q3 2015 for 2.25% of its portfolio. Scott Scher & Michael Prober Clovis Capital Management Lp owns 425000 shares or 2.78% of its portfolio. NY Mhr Fund Management Llc have 0.05% of their stock portfolio for 44499 shares. Further, Amici Capital Llc reported stake worth 2.32% of its US stock portfolio. The NY New Leaf Venture Partners Llc owns 712498 shares. Dynavax Technologies Corp is 15.17% of the manager’s US portfolio.

Business Profile

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. Its SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. Its advanced inflammatory disease candidate is AZD1419. Its pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Insitutional Activity: The institutional sentiment decreased to 1.02 in Q2 2016. Its down 0.04, from 1.06 in 2016Q1. The ratio dropped, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.

Reilly Financial Ltd Liability Company last reported 30 shares in the company. Pictet Asset Management Limited accumulated 0.02% or 246,492 shares. Teachers Advsr last reported 0% of its portfolio in the stock. Cqs Cayman L P has 105,082 shares for 0.14% of their US portfolio. Boston Prtnrs has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Victory Cap Mgmt accumulated 1,348 shares or 0% of the stock. Ameriprise Fincl accumulated 854,561 shares or 0.01% of the stock. Blackrock Institutional Trust Communications Na holds 942,830 shares or 0% of its portfolio. Group One Trading L P has invested 0.02% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Mutual Of America Cap Ltd Liability last reported 0.01% of its portfolio in the stock. Trexquant Inv Ltd Partnership reported 25,012 shares or 0.05% of all its holdings. California Public Employees Retirement accumulated 14,300 shares or 0% of the stock. Clough Capital Prtn Limited Partnership holds 0.19% or 243,884 shares in its portfolio. State Board Of Administration Of Florida Retirement Sys holds 15,836 shares or 0% of its portfolio. Susquehanna Intl Grp Llp holds 89,798 shares or 0% of its portfolio.

Insider Transactions: Since May 12, 2016, the stock had 2 buys, and 0 selling transactions for $57,940 net activity. The insider Gray Eddie bought $42,820. $15,120 worth of Dynavax Technologies Corporation (NASDAQ:DVAX) shares were bought by Janssen Robert.

Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on November, 3. They expect $-0.74 EPS, up 9.76% or $0.08 from last year’s $-0.82 per share. After $-0.75 actual EPS reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -1.33% EPS growth.

The stock decreased 3.67% or $0.41 during the last trading session, hitting $10.77. About 1.26M shares traded hands. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 34.73% since March 3, 2016 and is downtrending. It has underperformed by 43.08% the S&P500.

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company. The company has a market cap of $426.44 million. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. It currently has negative earnings. The Company’s development programs are focused on vaccines and cancer immunotherapy.

Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage

Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. $48 is the highest target while $22 is the lowest. The $34.33 average target is 218.76% above today’s ($10.77) stock price. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. Zacks upgraded Dynavax Technologies Corporation (NASDAQ:DVAX) rating on Wednesday, August 12. Zacks has “Hold” rating and $33 price target. JP Morgan downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) rating on Wednesday, April 27. JP Morgan has “Neutral” rating and $22 price target. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) earned “Sector Perform” rating by RBC Capital Markets on Thursday, April 28. The firm earned “Outperform” rating on Monday, November 30 by RBC Capital Markets.

According to Zacks Investment Research, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.”

DVAX Company Profile

Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment